Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of treprostinil palmitil inhalation powder in pulmonary hypertension associated with interstitial lung disease
2025-521558-40-00Phase 3Authorised
- Sponsor
- Insmed Incorporated
- Start
- Feb 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing Treprostinil palmitil inhalation powder with Placebo inhalation powder (2 arms). Primary endpoint: Change in 6-minute walk distance measured at peak exposure from baseline to Week 24. Planned start Feb 2026; status: authorised.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2025-521558-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521558-40-00.